Cargando…

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow

Despite the great success of immune-checkpoint inhibitor (ICI) treatment for multiple cancers, evidence for the clinical use of ICIs in acute myeloid leukemia (AML) remains inadequate. Further exploration of the causes of immune evasion in the bone marrow (BM) environment, the primary leukemia site,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Ling, Liu, Lian, Yao, Danlin, Zeng, Xiangbo, Zhang, Yikai, Lai, Jing, Zhong, Jun, Zha, Xianfeng, Zheng, Runhui, Lu, Yuhong, Li, Minming, Jin, Zhenyi, Hebbar Subramanyam, Sudheendra, Chen, Shaohua, Huang, Xin, Li, Yangqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416522/ https://www.ncbi.nlm.nih.gov/pubmed/34490086 http://dx.doi.org/10.3389/fonc.2021.686156

Ejemplares similares

Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia
por: Yao, Danlin, et al.
Publicado: (2020)

Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML
por: Tan, Jiaxiong, et al.
Publicado: (2020)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
por: Huang, Shuxin, et al.
Publicado: (2022)

Age related human T cell subset evolution and senescence
por: Li, Mingde, et al.
Publicado: (2019)

Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients
por: Jin, Zhenyi, et al.
Publicado: (2020)

Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment
por: Yao, Danlin, et al.
Publicado: (2023)

Upregulated TCRζ improves cytokine secretion in T cells from patients with AML
por: Chen, Shaohua, et al.
Publicado: (2015)

Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment
por: Yao, Danlin, et al.
Publicado: (2017)

Identification of TCR Vβ11-2-Dβ1-Jβ1-1 T cell clone specific for WT1 peptides using high-throughput TCRβ gene sequencing
por: Zhang, Yikai, et al.
Publicado: (2019)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Brauneck, Franziska, et al.
Publicado: (2021)

Age-Related Immune Profile of the T Cell Receptor Repertoire, Thymic Recent Output Function, and miRNAs
por: Xu, Yan, et al.
Publicado: (2020)

Generation of V α13/β21(+)T cell specific target CML cells by TCR gene transfer
por: Zha, Xianfeng, et al.
Publicado: (2016)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia
por: Liang, Chaofeng, et al.
Publicado: (2021)

Memory T cells skew toward terminal differentiation in the CD8+ T cell population in patients with acute myeloid leukemia
por: Xu, Ling, et al.
Publicado: (2018)

Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia
por: Xu, Ling, et al.
Publicado: (2014)

High Co-Expression of PDCD1/TIGIT/CD47/KIR3DL2 in Bone Marrow Is Associated with Poor Prognosis for Patients with Myelodysplastic Syndrome
por: Zhong, Mengjun, et al.
Publicado: (2023)

Changes in the MALT1-A20-NF-κB expression pattern may be related to T cell dysfunction in AML
por: Shi, Li, et al.
Publicado: (2013)

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
por: Shi, Li, et al.
Publicado: (2013)

Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer
por: Yin, Qingsong, et al.
Publicado: (2011)

Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia
por: Wang, Liang, et al.
Publicado: (2010)

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
por: Zhong, Zhenwei, et al.
Publicado: (2022)

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
por: Mu, Songlin, et al.
Publicado: (2022)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity
por: Subramanyam, Sudheendra Hebbar, et al.
Publicado: (2023)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Single‐Cell RNA‐Seq of T Cells in B‐ALL Patients Reveals an Exhausted Subset with Remarkable Heterogeneity
por: Wang, Xiaofang, et al.
Publicado: (2021)

The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2022)

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer
por: Peng, Hui, et al.
Publicado: (2022)

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
por: Yang, Zhenlin, et al.
Publicado: (2022)

TIGIT is a key inhibitory checkpoint receptor in lymphoma
por: Godfrey, James, et al.
Publicado: (2023)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

Increased TIGIT(+)PD‑1(+)CXCR5(‑)CD4(+)T cells are associated with disease activity in rheumatoid arthritis
por: Luo, Qing, et al.
Publicado: (2022)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
por: Zhao, Jingjing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3s1rq6v2ke37gttgrhqhff2gdj